[Immunological and serological tests for diagnosis of rheumatoid arthritis: MMP-3].
Momohara
Shigeki
S
Institute of Rheumatology, Tokyo Women's Medical University.
Yamanaka
Hisashi
H
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D019278:Matrix Metalloproteinase 3 / Q000097:blood*; D008727:Methotrexate / Q000627:therapeutic use; D011379:Prognosis; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D019714:Tissue Inhibitor of Metalloproteinases / Q000097:blood
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015415:Biomarkers; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D019714:Tissue Inhibitor of Metalloproteinases; D000069285:Infliximab; D019278:Matrix Metalloproteinase 3; D000068800:Etanercept; D008727:Methotrexate